ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results for Q2 2026 on Thursday, May 7th. The company reported earnings of -$0.93 per share, beating estimates of -$1.17 by $0.24. The company also reported revenue of $73,740,000, missing estimates of $81,590,728 by $-7,850,728.
You can see Quiver Quantitative's $ARWR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ARROWHEAD PHARMACEUTICALS Insider Trading Activity
ARROWHEAD PHARMACEUTICALS insiders have traded $ARWR stock on the open market 49 times in the past 6 months. Of those trades, 0 have been purchases and 49 have been sales.
Here’s a breakdown of recent trading of $ARWR stock by insiders over the last 6 months:
- CHRISTOPHER RICHARD ANZALONE (Chief Executive Officer) has made 0 purchases and 13 sales selling 175,944 shares for an estimated $11,661,762.
- JAMES C HAMILTON (Chief Medical Officer) has made 0 purchases and 9 sales selling 60,164 shares for an estimated $3,926,561.
- PATRICK O'BRIEN (COO) has made 0 purchases and 12 sales selling 49,493 shares for an estimated $3,123,349.
- MAURO FERRARI has made 0 purchases and 2 sales selling 16,280 shares for an estimated $1,020,512.
- MICHAEL S PERRY sold 16,250 shares for an estimated $991,737
- DANIEL JOSEPH APEL (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,095 shares for an estimated $934,285.
- VICTORIA VAKIENER has made 0 purchases and 3 sales selling 10,040 shares for an estimated $679,491.
- ADEOYE Y OLUKOTUN has made 0 purchases and 3 sales selling 10,000 shares for an estimated $676,623.
- WILLIAM D. WADDILL has made 0 purchases and 3 sales selling 8,367 shares for an estimated $566,038.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ARROWHEAD PHARMACEUTICALS Hedge Fund Activity
We have seen 241 institutional investors add shares of ARROWHEAD PHARMACEUTICALS stock to their portfolio, and 167 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,777,576 shares (-82.1%) from their portfolio in Q4 2025, for an estimated $383,573,270
- SLATE PATH CAPITAL LP removed 2,458,500 shares (-49.3%) from their portfolio in Q4 2025, for an estimated $163,219,815
- FRED ALGER MANAGEMENT, LLC added 1,526,164 shares (+497.4%) to their portfolio in Q4 2025, for an estimated $101,322,027
- MARSHALL WACE, LLP removed 1,312,985 shares (-91.4%) from their portfolio in Q4 2025, for an estimated $87,169,074
- SIREN, L.L.C. removed 1,169,404 shares (-43.8%) from their portfolio in Q4 2025, for an estimated $77,636,731
- BLACKROCK, INC. added 1,093,757 shares (+5.4%) to their portfolio in Q4 2025, for an estimated $72,614,527
- VESTAL POINT CAPITAL, LP added 900,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $59,751,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ARROWHEAD PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ARWR in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 12/17/2025
- Chardan Capital issued a "Buy" rating on 12/01/2025
- B of A Securities issued a "Buy" rating on 12/01/2025
- RBC Capital issued a "Outperform" rating on 11/19/2025
To track analyst ratings and price targets for ARROWHEAD PHARMACEUTICALS, check out Quiver Quantitative's $ARWR forecast page.
ARROWHEAD PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ARWR recently. We have seen 9 analysts offer price targets for $ARWR in the last 6 months, with a median target of $88.0.
Here are some recent targets:
- Brian Cheng from JP Morgan set a target price of $88.0 on 05/01/2026
- Michael Ulz from Morgan Stanley set a target price of $100.0 on 04/21/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 03/25/2026
- Madison El-Saadi from B. Riley Securities set a target price of $101.0 on 01/22/2026
- Edward Tenthoff from Piper Sandler set a target price of $110.0 on 01/13/2026
- Keay Nakae from Chardan Capital set a target price of $80.0 on 01/07/2026
- Andrea Tan from Goldman Sachs set a target price of $85.0 on 01/07/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
